Dolastatinol , CAS No.2759918-83-5

CAS: 2759918-83-5 Cat. No.: D1426635 Formula: C₄₃H₇₀N₆O₇S Molecular Weight: 815.12

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Overview

Dolastatinol is a synthetic analog of dolastatin 10 and low nanomolar inhibitor of tubulin polymerization.

Specifications

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

This product requires cold chain shipping. Ground and other economy services are not available.

Action Type

INHIBITOR

Names and Identifiers

Molecular Weight

815.12

Application Protocols

No tested application protocols, recommended dilutions, or control conditions are provided for this item in the catalog entry.

General starting points for small-molecule screening (user to validate):

• Stock preparation: 10–20 mM in anhydrous DMSO; aliquot and store at −20°C. Warm to room temperature and vortex before use.
• Cell-based assays: Begin with a wide concentration range (e.g., 0.1 nM to 10 µM) in half-log steps; maintain constant vehicle (DMSO) content across wells (typically ≤0.5–1% v/v).
• Biochemical assays: Establish buffer compatibility and include detergent (e.g., 0.01–0.05% Tween-20) if aggregation is suspected. Include counter-screens to detect assay interference.
• Analytical QC: Verify each fresh working solution by LC–MS when possible; track retention time and mass to confirm identity and monitor degradation.

These are generic guidelines for small molecules and are not item-specific performance claims. Optimize conditions according to your assay format and institutional SOPs.

Biological Roles

No item-specific biological mechanism or target annotation is provided in this catalog entry. The following comments reflect general, literature-level context for dolastatin-related scaffolds and should not be construed as claims about Dolastatinol without independent verification.

• Dolastatin-class background (literature):
  • Originally derived from marine sources, dolastatins and analogs are widely cited as potent cytoskeleton-active small molecules, often studied for their effects on microtubule dynamics. The specific activity profile of Dolastatinol is not provided here.
• Use as chemical biology tools:
  • Researchers may employ dolastatin-like compounds to probe tubulin-dependent processes, cell cycle modulation, and related signaling cascades in cell-based models. Potency and selectivity can vary dramatically with subtle structural changes; hence, item-specific validation is essential.
• Assay considerations:
  • Validate identity, purity, and concentration by orthogonal methods (LC–MS, quantitative NMR) before biological testing.
  • Establish concentration–response relationships and time-course profiles for your cell model. Include vehicle controls and, if applicable, known pathway modulators.
• Off-target and assay interference risk:
  • Peptidomimetic and heteroatom-rich compounds may display nonspecific binding or aggregation at higher concentrations. Employ controls such as detergent supplementation and counter-screens.

Important: This product is designated For research use only. No medical, diagnostic, or therapeutic use is intended or implied. Always consult the SDS and institutional biosafety guidance before in vitro or ex vivo testing.

Buffer Applications

This product is a discrete small-molecule compound, not a buffering reagent. Consequently, it is not used to prepare buffer systems or control pH directly.

Practical notes for assay buffers (general guidance):

• Vehicle preparation: Dissolve Dolastatinol first in a compatible organic stock solvent (commonly DMSO), then dilute into the assay buffer with vigorous mixing. Keep final organic solvent content as low as assay biology permits (often ≤0.5–1% v/v DMSO).
• Typical assay buffers: PBS, HBSS, or HEPES-buffered media are commonly used in cell-based assays. Add compound last, and verify that no precipitation occurs upon dilution.
• Protein binding: Consider adding carrier protein (e.g., 0.1–0.5% BSA) or low-level nonionic surfactant to mitigate nonspecific adsorption if recovery is poor.

No item-specific pKa or solubility data are provided; optimize buffer composition empirically for your application.

Green Alternatives

Because Dolastatinol is a discrete bioactive/library compound rather than a commodity solvent or reagent, “green alternative” selection typically focuses on how you formulate and handle the compound rather than replacing the compound itself.

Greener handling and formulation strategies (general guidance):

• Solvent choice hierarchy:
  • Prefer ethanol/water mixtures where solubility and assay biology permit.
  • Use DMSO at minimal feasible final concentrations (≤0.5–1% v/v) in assays to reduce solvent burden.
• Process minimization:
  • Aliquot concentrated stocks to avoid repeated freeze–thaw and waste.
  • Scale studies to microliter volumes in microplates where possible.
• Waste reduction:
  • Consolidate organic waste streams and adopt miniaturized analytics (UPLC vs HPLC) to decrease solvent usage.
• Packaging and storage:
  • Store at −20°C in tightly sealed vials; use inert gas backfill if stability requires to extend shelf life and reduce spoilage.

Tradeoffs:

• While ethanol or aqueous vehicles are greener than DMSO/DMF, they may not achieve adequate solubility for peptidomimetic scaffolds. Conduct small-scale solubility/stability screens to balance performance with sustainability.

Note: There are no item-specific alternative chemotypes listed for Dolastatinol in this catalog entry; substitution must be guided by your project’s SAR and target biology.

Pharmaceutical Uses

This product is sold strictly for research use only. No medical, diagnostic, or therapeutic applications are claimed or supported.

Relevant non-clinical, laboratory-facing contexts (general):

• Reference standard: May serve as an internal or external standard in analytical methods during discovery research, pending availability of purity and identity confirmation.
• Formulation research: Early-stage preformulation studies (solubility, stability in vehicles, adsorption to plastics) can be performed to support in vitro dosing studies. Results are compound- and lot-specific.
• Impurity profiling/method development: Useful for developing and qualifying LC–UV/LC–MS methods that can later be applied to related analogs within a SAR series.

Regulatory/compendial status:

• There is no pharmacopeial monograph or compendial status specified for Dolastatinol in this catalog entry.
• Any use in GLP/GMP environments requires independent qualification of identity, purity, and stability, and is outside the scope of this research-only product.

Physical Properties

Only list values with clear sourcing; no catalog specifications are provided for this item.

Item-specific (from Product Data):

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.

Literature/general expectations for dolastatin-like small peptidomimetics (NOT item specifications):

• Physical state: Often obtained as off-white to white solids or films; hygroscopicity can vary by analog.
• Solubility: Frequently soluble in polar aprotic solvents (e.g., DMSO, DMF) and alcoholic media; aqueous solubility is typically limited unless salts are formed or formulation aids are used. Always verify experimentally for Dolastatinol.
• Partitioning: Peptidomimetic scaffolds can exhibit moderate to high polarity with localized lipophilic regions; logP/logD values are highly structure-dependent (no specific value available for this item).
• UV/Vis: Amide-rich frameworks typically show strong peptide n→π* and π→π* bands in the 190–220 nm region; heteroaromatic substitutions (if present) may introduce additional bands. Exact spectra for Dolastatinol are not available here.

Critical note:

• No boiling point, melting point, density, pKa, refractive index, or solubility numbers are specified for this item; consult the CoA/Spec Sheet and SDS, or determine empirically under your lab’s QA protocols.

Quality & Grades

Item-specific quality information provided in the listing:

• Grade/Purity: Not specified for this item; refer to CoA/Spec Sheet.

How to interpret common grades (general guidance):

• Research grade: Suitable for exploratory research, screening, and method development; acceptance criteria are defined internally and documented on the CoA.
• ≥95% (typical for library compounds): Adequate for primary screening; verify by HPLC/LC–MS. If your application is SAR-critical or quantitative biology, consider ≥98%.
• HPLC grade (solvent) vs compound purity: Note that “HPLC grade” refers to solvents, not to compound purity. For actives, purity is usually given as area% by HPLC/UPLC.
• Residual solvents/metals/water: For small-molecule libraries, these are not typically specified unless requested. If your assay is metal- or water-sensitive, request the CoA or perform in-house KF and ICP-MS.

What to request/verify for Dolastatinol (practical tips):

• Purity method and chromatograms (HPLC/UPLC), UV trace, and mass confirmation (ESI–MS/HRMS).
• Structural confirmation (1H/13C NMR, and where relevant, 2D NMR). If stereochemistry is critical, ask for optical rotation or chiral HPLC.
• Residual solvent and counter-ion content when preparing mass-normalized dosing solutions.

Stabilizers/inhibitors:

• Not specified for this item; refer to CoA/Spec Sheet. If present, they will be declared on the CoA.

Reaction & Applications

This product is sold as a member of a small-molecule/compound library for research. It is not primarily intended as a synthetic reagent. Accordingly, classical synthetic “reaction applications” (e.g., as a solvent, catalyst, or stoichiometric reagent) are not typically applicable.

Research/application contexts (general, literature-level for dolastatin-class probes; confirm suitability for Dolastatinol with your protocols):

• Chemical biology screening: Use in high-content or viability assays to explore cytoskeleton-associated pathways or related phenotypes; adhere to appropriate potency handling.
• Target engagement and mechanism studies: If structure and activity are confirmed for your lot, apply in target engagement assays (e.g., cellular thermal shift or biochemical binding) with proper controls.
• Analytical reference: Can serve as a reference material for LC–MS method development in compound libraries (retention time, ionization behavior, fragmentation), pending availability of purity/mass confirmation.

Practical tips:

• Prepare concentrated DMSO stocks (e.g., 10–20 mM), verify solubility visually, and confirm by LC–UV or LC–MS.
• Include vehicle controls and, when applicable, scaffold-related positive controls from the literature.
• For plate-based assays, pre-wet tips and minimize adsorption by using low-binding plastics.

If you intend to derivatize or use Dolastatinol in synthetic schemes, obtain the full structural data (CoA and, if needed, primary literature) and verify functional groups before planning chemistry.

Reaction Conditions

Classical reaction conditions (solvent, catalyst, temperature) are not applicable because Dolastatinol is provided as a completed small molecule rather than a reagent intended to facilitate other reactions.

For laboratory use as a research compound (general guidance):

• Stock solution preparation: Often prepared in anhydrous DMSO at 10–20 mM; confirm complete dissolution visually and analytically (LC–UV/LC–MS). Filter (0.22 µm) if particulates persist.
• Working concentrations: Determined empirically for your assay type. Establish concentration–response curves and avoid exceeding solubility limits to prevent aggregation/precipitation artifacts.
• Temperature/light: Prepare and handle at ambient temperature, minimizing exposure to light until stability is characterized. Store long-term at −20°C as specified.
• Stability checks: Periodically verify integrity by LC–MS after freeze–thaw cycles or extended storage. Track water uptake in DMSO stocks (Karl Fischer) if you require stringent control.

No item-specific kinetic, stability, or degradation pathway data are provided in this listing; generate in-house under your QA/QC framework.

Safety & Handling

Authoritative safety information resides in the SDS. The following summarizes what is and is not specified for this catalog item and offers general laboratory best practices.

Item-specific hazard data (from Product Data):

• Signal word: Not specified for this item; refer to SDS.
• H-statements: Not specified for this item; refer to SDS.
• GHS classification: Not specified for this item; refer to SDS.
• Pictograms: Not specified for this item; refer to SDS.

Storage and shipping (item-specific):

• Storage: Store at −20°C.
• Shipping: Ice chest + ice pads (keep cold; avoid prolonged ambient exposure).

General lab safety guidance for bioactive small molecules (literature/best practice, not item-specific):

• PPE: Laboratory coat, safety glasses, and appropriate chemical-resistant gloves (e.g., nitrile). Use a certified chemical fume hood for weighing, dissolving, or aliquoting powders/solutions that may be irritant or potent.
• Inhalation/dermal/ingestion: Avoid dust/aerosols; minimize skin contact. Wash thoroughly after handling.
• Weighing/solution prep: If potency is unknown, treat as potentially hazardous at low dose; use closed containers, weigh boats with covers, and antistatic measures.
• Incompatibilities: Strong oxidizers and reducing agents may react with peptidic/heteroatom-rich compounds; avoid exposure to strong acids/bases unless intended. Prevent moisture ingress to maintain integrity.
• First aid (general): Move to fresh air if inhaled; rinse skin with water for ≥15 minutes upon contact; flush eyes with water for ≥15 minutes and seek medical advice; if swallowed, rinse mouth and seek medical attention. Provide the SDS to responders.

Waste: Collect in compatible, clearly labeled containers; dispose via licensed chemical waste services according to institutional and local regulations.

Solvent Selection

Item-specific solubility data are not provided. The guidance below reflects common practice for peptide-like small molecules used in screening. Always verify solubility and stability experimentally for your exact lot of Dolastatinol.

• Primary stock solvent (screening workflows):
  • DMSO is typically preferred for small-molecule libraries due to high solvating power, compatibility with assay plates, and low volatility. Begin with 10–20 mM target concentration and adjust.
• Cosolvent strategies:
  • If DMSO solubility is limited, consider DMF or NMP (for intermediate stocks), then dilute into assay buffers with stepwise mixing.
  • For aqueous delivery, use minimal DMSO (≤0.5–1% v/v final if assay-sensitive), and consider solubilizing excipients (0.01–0.05% Tween-80 or 0.1–1% Pluronic F-127) where biologically acceptable.
• pH adjustment:
  • If ionizable groups are present (common in peptidomimetics), modest pH adjustment can improve solubility. Prepare acidified (e.g., 0.1% TFA or acetic acid) or basified (e.g., 0.1% DEA) DMSO/aqueous mixtures as needed, validating stability.
• Filtration:
  • 0.22 µm PTFE or PES syringe filters are generally compatible. Avoid nylon if strong acid is present.
• Stability considerations:
  • Minimize freeze–thaw cycles; aliquot DMSO stocks. Protect from moisture and light until stability is known.

Comparison (general):

• DMSO: highest success rate for library compounds; hygroscopic.
• DMF: strong solvent, but more noxious; often for intermediate stocks only.
• EtOH/MeOH: greener but may be insufficient for hydrophobic/peptidic scaffolds.

Storage & Reconstitution

Item-specific conditions:

• Storage: Store at −20°C.
• Shipping: Ice chest + ice pads.

Reconstitution (general guidance for small molecules; not item-specific):

• Solvent: Start with anhydrous DMSO for primary stocks unless item-specific solubility data indicate otherwise. If successful, prepare 10–20 mM stocks.
• Aliquoting: Dispense into single-use aliquots (e.g., 10–50 µL) in low-bind tubes or sealed 96-well plates to limit freeze–thaw cycles and moisture ingress.
• Thawing/handling: Warm sealed vials to room temperature before opening to avoid condensation. Vortex and briefly sonicate if needed to fully dissolve.
• Dilution: Add stock to pre-equilibrated buffer or media with rapid mixing to avoid local supersaturation. Keep final DMSO content as low as compatible with your assay.

Stability notes:

• Light/moisture: Until stability is established, protect from light and moisture. Consider inert gas backfill for partial vials.
• Freeze–thaw: Minimize cycles; discard aliquots showing precipitation or degraded LC–MS profiles.

Specifications not provided:

• Purity, water/peroxide/metal limits, and detailed stability profile: Not specified for this item; refer to CoA/Spec Sheet.

Research use only: For laboratory research use; not for human or veterinary use.

Structure & Identity

Short description: Dolastatinol is listed in our small-molecule/compound library category. Item-specific structural identifiers are not provided in the catalog entry; consult the CoA/SDS if available.

• SKU: D1426635
• CAS: 2759918-83-5
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES: Not specified for this item; refer to CoA/Spec Sheet.
• InChIKey: Not specified for this item; refer to CoA/Spec Sheet.
• Synonyms: Not specified for this item; refer to CoA/Spec Sheet.

Structural features (general literature context, not item-specific):

• “Dolastatin-” nomenclature commonly refers to marine-derived small peptidic/peptidomimetic cytoskeleton-active scaffolds. The exact substitution pattern and stereochemistry for Dolastatinol are not specified in this listing.
• Typical dolastatin-class molecules feature multiple amide (peptide) linkages and unusual amino acid residues; some analogs include secondary alcohols, thiazole/heterocycles, or methylated side chains (literature, scaffold-level observation). This may or may not apply to Dolastatinol; verify against the CoA/SDS.

2D structure (descriptive, literature-level):

• Without an item-specific structure, a precise 2D description cannot be given. If Dolastatinol follows dolastatin-like motifs, expect a linear or near-linear peptidomimetic backbone bearing N-acyl termini and several stereogenic centers (literature). Please confirm the exact structure from primary references or the product’s CoA.

Synthetic Utility

Dolastatinol is offered as a finished small molecule for biological research and screening; it is not primarily a synthetic building block. Without an item-specific structure or functional group disclosure, synthetic planning guidance would be speculative.

General comments (literature-level for peptidomimetic scaffolds):

• Functional group considerations: Dolastatin-related compounds often contain multiple amide linkages and stereocenters. Late-stage functionalization can be challenging due to chemoselectivity constraints and epimerization risks.
• Derivatization potential: If a free amine, alcohol, or carboxylate is present (structure-dependent), common transformations include acylation, carbamate/urethane formation, esterification, or prodrug conjugation. Confirm functionality by NMR before attempting.
• Conjugation chemistry: For analogs bearing nucleophilic handles, NHS-ester coupling, click chemistry (azide–alkyne), or thiol–maleimide strategies are typical. None of these are asserted for Dolastatinol without structural confirmation.

If your intent is to use Dolastatinol as a synthetic intermediate, obtain the full structural dossier (CoA, spectra, and, where available, primary literature) and run small-scale tests to establish compatibility and stability.

Target Specificity

Only provide target information if supplied in the product data. For this item:

• Target/Pathway: Not specified for this item; refer to CoA/Spec Sheet or primary literature.
• Species reactivity: Not specified for this item; refer to CoA/Spec Sheet.
• Assay validation: Not specified for this item; refer to CoA/Spec Sheet.

Note: Literature on dolastatin-class molecules frequently discusses microtubule-related biology, but no specific target annotation is provided or claimed here for Dolastatinol. Users should establish target specificity experimentally in their own systems.